Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
Khanh T DoClaire ManuszakEmily ThrashAnita Giobbie-HurderJiani HuSarah KellandAllison PowersAdrienne de JongeGeoffrey I ShapiroMariano SevergniniPublished in: Cancer immunology, immunotherapy : CII (2021)
ClinicalTrials.gov identifier: NCT03495323. Registered April 12, 2018.